Brivaracetam
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Brivaracetam
- Pharmacist Assessment Report
- Brivaracetam: SV2A modulator (antiseizure drug) → beta-ketothiolase deficiency
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Brivaracetam: SV2A modulator (antiseizure drug) → beta-ketothiolase deficiency
One-Sentence Summary
Brivaracetam is an antiseizure medicine that acts on the synaptic vesicle protein SV2A. The TxGNN model predicts it may be relevant to beta-ketothiolase deficiency, but no clinical trials and no publications were found to support this direction, so it rests on the model prediction alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | beta-ketothiolase deficiency |
| TxGNN Prediction Score | 0.9914 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for brivaracetam is not available in the data compiled for this report. Based on general knowledge, brivaracetam binds the synaptic vesicle protein SV2A and is used as an antiseizure drug.
Beta-ketothiolase deficiency is an inborn error of ketone body and isoleucine metabolism caused by an enzyme defect. It is not primarily a seizure disorder, and SV2A modulation has no plausible mechanistic connection to this enzyme defect. The high score is most likely an artifact of the model rather than a true therapeutic signal, and no clinical or literature evidence supports it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
At least 20 valid single-ingredient licences are recorded; the list below may be partial. Up to 5 are shown.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 26357 | Brivanext 50mg Tablet | Strip of 10 tablets | Not recorded |
| 28184 | Brivatab 100mg Tablet | Strip of 10 tablets | Not recorded |
| 28471 | Bripca 75mg Tablet | Strip of 14 tablets | Not recorded |
| 26854 | Briviact 75mg Tablet | Strip of 14 tablets | Not recorded |
| 28419 | Brivup 10mg Injection | Vial of 5 ml injection | Not recorded |
Safety Considerations
- Drug Interactions: 69 interactions are recorded. Examples at moderate level include morphine, opium, dronabinol, nabilone, metoclopramide, promethazine, clopidogrel, ethanol, sibutramine, difenoxin and diphenoxylate (additive central nervous system effects are a general concern with sedating agents). Minor-level examples include proton pump inhibitors (omeprazole, esomeprazole, lansoprazole, pantoprazole, dexlansoprazole), tolbutamide, chlorpropamide and cilostazol.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score but no supporting trials or publications, and there is no plausible mechanistic link between SV2A modulation and this metabolic enzyme defect. It should not advance on the current evidence.
To proceed, the following is needed:
- Any preclinical or clinical study that directly addresses beta-ketothiolase deficiency
- A credible mechanistic rationale linking brivaracetam to the disease
- Detailed mechanism of action data
- Package insert warnings and contraindications from the India licences
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.